MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

List is tentative, and subject to change at any time.

SEARCH:

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

Cincinnatti Children's

Cincinnati Children's

Small molecule chaperones restore acid-β-glucosidase activity

Cincinnati Children's Hospital

Gaucher disease (GD) is an inherited disorder where the body does not make enough glucocerebrosidase (GCase), an enzyme that breaks down fatty chemicals in the body.

Read more

Serine protease inhibitors treats eosinophilic esophagitis

Cincinnati Children's Hospital

A critical component of normal esophageal function is a protective epithelial barrier that prevents damage to the underlying tissue due to outside environment exposure such as foreign antigens and microorganisms.

Read more

New approach enhances vaccination

Cincinnati Children's Hospital

Vaccines must elicit immune responses of a sufficient magnitude and quality to prevent or treat disease. While existing vaccine technologies are capable of achieving this goal for many diseases, these strategies have thus far proven inadequate against global threats like HIV and cancer.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

ColoradoState

Colorado State University

New cell therapy battles bacterial infections

Validus Cellular Therapeutics (Colorado State University)

For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics, which are susceptible to resistance and are limited accessing infections.

Read more

Clinical trials show promise for Innocell cancer vaccine

PhotoPharma (Colorado State University)

PhotonPharma’s Innocell involves sampling a patient’s tumor cells, inactivating them so that they are unable to replicate, then administering them back to the patient.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

IndianaIndianaIndiana

Indiana University

Vasculonics develops new therapy for acute kidney and chronic diabetic kidney disease with clinical candidates

Vasculonics (Indiana University)

Vasculonics is an Indiana-based biotech formed out of technology licensed from Indiana University.

Read more

New compound inhibits pancreatic cancer

EQon Pharmaceuticals (Indiana University)

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortalities of all malignancies, with aggressive biology, resistance to therapeutic agents, and a mere 5-year survival of 8-9%.

Read more

New approach has potential to cure pulmonary arterial hypertension

Drax Therapeutic Inc. (Indiana University)

Pulmonary arterial hypertension (PAH) affects 200, 000 people annually and there is no cure for this condition.  Researchers at Indiana University and University of Illinois at Chicago, have identified a potential drug for curing PAH.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

Kansas State

Kansas State University

New vaccine approach targets ETEC-related diarrhea

Kansas State University

Researchers at Kansas State University have developed a structure-based multiepitope fusion antigen (MEFA) technology for vaccines against Enterotoxigenic Escherichia coli (ETEC) bacteria.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

MayoClinic

Mayo Clinic

Small molecule Wnt modulators to treat Alzheimer’s

Mayo Clinic

Mayo Clinic researchers have developed a small molecule modulator for use in treating and preventing a variety of Wnt-related conditions such as Alzheimer’s Disease (AD) and other neurodegenerative disorders, traumatic and ischemic brain injury, as well as bone loss disorders.

Read more

New approach improves CAR T cancer therapies

Mayo Clinic

Mayo Clinic researchers have developed a novel regimen by which oncolytic virotherapy can be used as a potent immunological adjuvant to improve the efficacy of CAR T cell therapy against solid tumors.

Read more

MSC CARs engineered with a CAR enhances immunosuppression

Mayo Clinic

Mesenchymal Stromal Cells (MSCs), have been used in cell therapy for treatment of various inflammatory conditions. Chimeric Antigen Receptor (CAR) engineered MSCs have the potential to create an MSCs with higher immunosuppression activity and in-vivo persistence.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

Medical College of Wsiconsin

Medical College of Wisconsin

Engineered bacterial strain eliminates drug resistance in GI tract

Medical College of Wisconsin

Medical College of Wisconsin inventors have developed a novel biotherapeutic for eliminating antibiotic-resistant enterococci from the GI tract.

Read more

New mitochondria-targeted therapeutics will help lung, other cancers

Medical College of Wisconsin

Medical College of Wisconsin inventors have developed novel small molecule therapeutics that will help treat small cell lung cancer, among other cancers.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

Ohio State

Ohio State University

TTK kinase inhibitor to treat hematological malignancies

Ohio State University

The TTK kinase is critical for proper function of the spindle assembly checkpoint, and its upregulation is associated with poor clinical outcomes in a variety of cancer types.

Read more

DHODH inhibitors to treat hematological malignancies

Ohio State University

Dihydroorotate dehydrogenase (DHODH) is a key enzyme in the de novo pyrimidine synthesis pathway.

Read more

Therapeutic cancer vaccine platform is customizable

Ohio State University

B cells are primarily known for their robust adaptive immune response through antibody production; however, they are often overlooked among the body’s professional antigen-presenting cell (APC) populations.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

PurduePurdue

Purdue University

Therapeutic targets metastatic prostate cancer

Purdue University

Researchers at Purdue University have developed a targeted therapeutic option for treating metastatic prostate cancer, the second leading cause of cancer death for men in the United States.

Read more

Selective GRK5 inhibitors can treat heart failure, breast cancer

Purdue University

Researchers at Purdue University have developed selective small molecule inhibitors of G protein-coupled receptor kinase 5 (GRK5) for preventing heart failure and treating breast cancer.

Read more

Human chimeric antigen receptor neutrophils to treat cancer

Purdue University

Researchers at Purdue University have developed chimeric antigen receptor (CAR) neutrophils for the targeted treatment of cancer.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

ColoradoColorado

University of Colorado-Boulder

Prevent, alleviate side effects of radiation or radiotherapy

University of Colorado-Boulder

Using C. elegans as an animal model to study radiation-induced bystander effects (RIBE), researchers at the University of Colorado Boulder have identified a highly conserved cysteine protease, cathepsin B, as the first RIBE factor.

Read more

Novel selective HDAC6 inhibitors show promise for cancer and beyond

University of Colorado-Boulder

The researchers of the University of Colorado developed a series of hydroxamic acid derivatives as HDAC6 selective inhibitors.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

IowaIowaIowa

University of Iowa

Non-viral formulation delivers lubricin genes

University of Iowa

Post-traumatic osteoarthritis weakens the regulation of lubricin gene and increases shear stress within the joints.

Read more

BMP-2 RNA enhances bone regeneration

University of Iowa

Inventors at the University of Iowa have developed an RNA-based therapeutic that can be used in medical and dental applications.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

KansasKansas

University of Kansas

Novel antiviral therapeutics target SARS-CoV-2 infections

University of Kansas

Remdesivir is currently the only FDA-approved drug for treating COVID-19. While remdesivir improves recovery time, it does not significantly reduce death rates in hospitalized adults. Researchers at the University of Kansas have produced novel antivirals that shows promise as a COVID-19 treatment.

Read more

RNA-binding protein inhibitors slow tumor growth in metastatic cancers

University of Kansas

Despite recent therapeutic advances in cancer treatment, metastatic cancer remains the primary cause of cancer deaths.

Read more

Unique cadherin peptides enhance brain delivery of therapeutic molecules, antibodies

University of Kansas

Therapeutic proteins have been used to successfully treat a variety of neurodegenerative diseases.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

KentuckyKentucky

University of Kentucky

Novel mPGES-1 inhibitor targets pain, inflammatory diseases

University of Kentucky

It has been proposed that prostaglandin E2 (PGE2), known as the principal proinflammatory prostaglandin, is implicated in pain response and also plays a role in inflammatory diseases.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

MinnesotaMinnesota

University of Minnesota

Humanized antibodies to treat diabetes, range of tissue injuries

University of Minnesota

SerpinB13 is a protease inhibitor linked to autoimmune inflammation and Type 1 diabetes (T1D).

Read more

Agmatine-based pain treatment avoids opioid addiction

University of Minnesota

The search for better analgesics has focused on non-addictive alternatives. Agmatine, the decarboxylated product of arginine, is a potential candidate for novel therapeutics.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

MissouriMissouri

University of Missouri

Dual-biomarker targeting agent helps diagnose, treat prostate cancer

University of Missouri

A dual diagnostic and therapeutic compound binds GRPr and PSMA with high specificity and sensitivity.

Read more

Gene therapy improved with new AAV hybrid vector system

University of Missouri

Novel dual- and tri-AAV hybrid vector systems increase the upper size limit of gene constructs from <5kb to <15kb.

Read more

Novel antibiotics target beta-lactamase

University of Missouri

Researchers at the University of Missouri have developed novel inhibitors of beta-lactamase, a bacterial enzyme that provides resistance to β-lactam antibiotics.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

NebraskaNebraska

University of Nebraska Medical Center

ProGel delivers meds for long-term local effect

Ensign Pharmaceutical (University of Nebraska Medical Center)

ProGel is a platform technology with a diverse spectrum of drug payloads, such as steroids, statins, antioxidants, opioids, chemotherapeutics, and hormones.  Ensign Pharmaceutical’s initial product focuses on managing osteoarthritis pain, incorporating a potent steroid, dexamethasone, into the formulation.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

SouthDakota

University of South Dakota

New approach improves drug delivery for dental applications

University of South Dakota

Microparticles based on hydroxyapatite, calcium carbonate, or calcium citrate and cross-linked gels loaded with a drug such as eugenol or arginine are able to occlude dentinal tubules and release on-demand a cargo drug to the oral cavity and to the pulp of the tooth, providing both desensitizing, antibacterial or any other effect depending on the drug cargo.

Read more

Universities

Cincinnati Children's Hospital Medical College of Wisconsin University of Iowa University of Missouri
Colorado State University Ohio State University University of Kansas University of Nebraska Med Center
Indiana University Purdue University University of Kentucky University of South Dakota
Kansas State University University of Colorado-Boulder University of Minnesota University of Wisconsin
Mayo Research and Education

WisconsinWisconsin

University of Wisconsin

Nanoparticles deliver bioactive molecules

University of Wisconsin (WARF)

A new hybrid nanocapsule uses a silica, metal and organic framework designed to deliver protein, nucleic acid or hydrophilic drugs.

Read more

Paclitaxel prodrug enhances anticancer efficacy

University of Wisconsin (WARF)

A new formulation of paclitaxel fuses the drug to an oligo-lactic acid (oLA) encapsulated in a PEG-PLA micelle.

Read more

New treatment for Status Epilepticus ‘starves’ problematic neurons

University of Wisconsin (WARF)

This technology uses 2-deoxy-D-glucose (2DG) as a novel treatment for Status Epilepticus (SE).

Read more

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights

An error has occured.